Abstract：
The treatment of head and neck and salivary gland tumours is complicated and is constantly evolving. Prognostic and predictive indicators of response to treatment are enormously valuable for designing individualized therapies, which justifies their research and validation. Some biomarkers, such as p16, Epstein-Barr virus, PD-L1, androgen receptors and HER-2, are already used routinely in clinical practice. These biomarkers, along with other markers that are currently under development, and the massively parallel sequencing of genes, ensure future advances in the treatment of these neoplasms. In this consensus, a group of experts in the diagnosis and treatment of tumours of the head and neck and salivary glands were selected by the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica - SEAP) and the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica - SEOM) to evaluate the currently available information and propose a series of recommendations to optimize the determination and daily clinical use of biomarkers.
摘要：
头颈部和唾液腺肿瘤的治疗是复杂的，并且在不断发展。对治疗反应的预后和预测指标对于设计个性化疗法非常有价值。这证明了他们的研究和验证。一些生物标志物，如p16，爱泼斯坦-巴尔病毒，PD-L1、雄激素受体和HER-2已经在临床实践中常规使用。这些生物标志物,以及目前正在开发的其他标记，以及基因的大规模平行测序，确保这些肿瘤治疗的未来进展。在这个共识中,西班牙病理学会(SociedadEspañoladeAnatomiaPatológica-SEAP)和西班牙医学肿瘤学会(SociedadEspañoladeOncologoíaMédica-SEOM)选择了一组诊断和治疗头颈部和唾液腺肿瘤的专家,以评估现有信息,并提出一系列临床使用建议,以优化确定和每日生物标志物.
